Government Notifies Retail Price Caps for 39 Medicines Across Key Therapeutic Categories

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 39 drug formulations under the Drugs (Prices Control) Order (DPCO), 2013, as per a CNBC TV18 report.  

The notification was issued by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers, on 8 July 2026. The order applies to new drug formulations and sets the maximum retail price that manufacturers can charge. 

Medicines Across Different Treatment Areas 

The list includes medicines used for hypertension, diabetes, heart disease, bacterial infections and HIV treatment. The notification also covers multiple other medicines supplied as tablets, capsules, and injections. 

Few among the formulations notified are Tenecteplase (TNK-TPA) Injection, Combikit Darunavir, Ritonavir and Dolutegravir Tablets, Amoxicillin and Potassium Clavulanate Dispersible Tablets, and combinations containing Aspirin, Atorvastatin, Telmisartan, Amlodipine, Metoprolol Succinate and Ezetimibe.  

Prices Specified for Individual Formulations 

The order provides the strength, dosage form, manufacturer or marketing company and retail price for each product. For example, Amlodipine, Telmisartan and Metoprolol Succinate Extended Release Tablets have been priced at ₹12.03 per tablet.  

Two formulations of Amoxicillin and Potassium Clavulanate Dispersible Tablets have been fixed at ₹27.31and ₹19.53 per tablet. Aspirin Gastro-Resistant and Atorvastatin Capsules have been capped at ₹3.67 per capsule, while Atorvastatin and Ezetimibe Tablets have been priced at ₹31.73 and ₹21.36 per tablet, depending on the strength. 

Conditions for Manufacturers 

According to the notification, manufacturers of these formulations are required to fix the retail price at or below the level specified by the NPPA.  

The ministry also said that any existing manufacturer launching the same new drug within 12 months from the publication of the notification in the Official Gazette will be allowed to market it only if the retail price does not exceed the notified ceiling. 

Follows Earlier Price Notification 

The latest order comes after the NPPA fixed retail prices for 42 drug formulations in May 2026 under the DPCO, 2013. The authority periodically notifies retail prices for new formulations after examining applications submitted by manufacturers. 

Read More: Indian Railways Approves ₹206 Crore Kavach Rollout for Northern Railway! 

Conclusion 

Through this notification, the NPPA has prescribed retail prices for 39 new drug formulations across multiple therapeutic categories. The revised prices take effect under the provisions of the Drugs (Prices Control) Order, 2013. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.